SUTRO BIOPHARMA INC
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
STRO$9.62+4.6%Stored close · as of Nov 6, 2026
Contents
Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue | $153,731 | $67,772 | $61,880 |
| Operating expenses | |||
| Research and development | 180,425 | 137,171 | 104,400 |
| General and administrative | 62,584 | 59,544 | 56,004 |
| Total operating expenses | 243,009 | 196,715 | 160,404 |
| Loss from operations | (89,278) | (128,943) | (98,524) |
| Interest income | 14,510 | 3,455 | 577 |
| Unrealized gain (loss) on equity securities | 9,917 | 12,130 | (4,454) |
| Non-cash interest expense related to the sale of future royalties | (12,570) | - | - |
| Interest and other income (expense), net | (11,180) | (3,346) | (3,137) |
| Loss before provision for income taxes | (88,601) | (116,704) | (105,538) |
| Provision for income taxes | 18,192 | 2,500 | - |
| Net loss | $(106,793) | $(119,204) | $(105,538) |
| Net loss per share, basic and diluted | $(1.78) | $(2.35) | $(2.29) |
| Weighted-average shares used in computing basic and diluted net loss per share | 60,163,542 | 50,739,185 | 46,119,089 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.